Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Javitt knows a lot about public health policy because one of his professors chided him when he heard that the young medical student was going to India to help cure patients with glaucoma.
“All you’ll be doing is helping a blind beggar see,” the thoughtless man told Javitt.
Enraged, Javitt conducted a study that proved that restoring eyesight to Indian patients with the eye disease increased their family earnings by 1,500%. The patient, now able to see, was able to work – and the pressure on his family to care for him was lifted, helping the entire family advance in life.

https://m.jpost.com/health-science/neurorx-on-the-cusp-of-releasing-a-life-saving-covid-19-treatment-644470/amp

Researchers have recently reported that injecting a neuropeptide called vasoactive intestinal peptide (VIP) into the eyes of mice enhanced the survival rate of the corneal transplant. The study also listed other benefits of VIP, including accelerated endothelial wound closure, protection of corneal endothelial cells (CEnCs) and a notable improvement in the clarity of the corneal transplant.

CEnCs are responsible for keeping the corneal graft transparent, and VIP helps protect these cells from certain cell deaths. Researchers are also looking into the benefits VIP can provide to the donated corneas. They have reason to believe that vasoactive intestinal peptides can be used to preserve the endothelial cells in these donated grafts, making them more likely to survive the transplant.

https://www.myopiainstitute.com/eye-care/improving-corneal-transplant-survival-using-new-techniques/amp/

The global myopia and presbyopia treatment market size valued at USD 15.5 billion in 2018 and is expected to grow at a compound annual growth rate (CAGR) of 7.7% from 2019 to 2026.

https://www.grandviewresearch.com/industry-analysis/myopia-presbyopia-treatment-market